The rationale for pathogen inactivation treatment of platelet components-introduction

Seminars in Hematology

Volumn 38, Issue 4 SUPPL. 11, 2001, Pages 1-3

  Barbara, John ^a  

^a NHS BLOOD AND TRANSPLANT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMOTOSALEN; PSORALEN DERIVATIVE; THROMBOCYTE CONCENTRATE; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIGEN DETECTION; BLOOD COMPONENT THERAPY; EDITORIAL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MICROBIOLOGICAL EXAMINATION; PRIORITY JOURNAL; RISK ASSESSMENT; SAFETY; SEROLOGY; THROMBOCYTE TRANSFUSION; VIRUS DETECTION; VIRUS INACTIVATION; VIRUS TRANSMISSION;

EID: 0035185040     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0037-1963(01)90117-9     Document Type: Editorial

References (5)

1. Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long-wavelength ultraviolet light
2. Photochemical inactivation of bacteria and HIV in buffy-coat-derived platelet concentrates under conditions that preserve in vitro platelet function
3. Prevention of posttransfusion CMV in the era of universal WBC reduction: A consensus statement
4. BSE and transmission through blood